Almac Group Launches Almac Adapt
Almac Clinical Services, part of the Almac Group, has today announced the launch of Almac Adapt - a Just in Time Manufacturing (JTM) solution.
The Almac Adapt solution offers the timely generation and delivery of kits to sites and patients worldwide. By shifting the focus from what we do to why we do it, Almac Adapt embodies this understanding in a patient-centric culture by translating itself into an actionable and proactive manufacturing, packaging, labelling and distribution solution.
This solution manipulates the global supply chain and bridges the gap between supply and demand - optimizing on-time delivery for patients, inventory flexibility for sites whilst achieving key time-based milestones for the sponsor.
To find out more about this service, please visit www.almacgroup.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
